Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.43 |
| ▸ | MDM4 | O15151 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30414354 | 0.96 | PTPN1 (0.42) | CASP3PTPN1MDM4TP53 | |
| SCHEMBL31506327 | 0.93 | CASP3 (0.49) | CASP3MDM4TP53TNF | |
| SCHEMBL30250366 | 0.93 | CASP3 (0.42) | CASP3PTPN1MDM4TP53TNF | |
| SCHEMBL30053999 | 0.93 | CASP3 (0.46) | CASP3PTPN1MDM4TP53 | |
| SCHEMBL30054142 | 0.92 | PTPN1 (0.39) | CASP3PTPN1MDM4TP53 | |
| SCHEMBL30054440 | 0.92 | CASP3 (0.49) | CASP3PTPN1MDM4TP53 | |
| SCHEMBL30277427 | 0.92 | CASP3 (0.45) | CASP3PTPN1TNF | |
| SCHEMBL30786572 | 0.91 | PTPN1 (0.43) | CASP3PTPN1MDM4TP53TNF | |
| SCHEMBL30517260 | 0.90 | PTPN1 (0.44) | CASP3PTPN1MDM4TP53 | |
| SCHEMBL29812453 | 0.90 | CASP3 (0.53) | CASP3PTPN1MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125423-A1 | PEPTIDES FOR INCRETIN SYNTHESIS | LILLY CO ELI (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4598938-A2 | PEPTIDES FOR INCRETIN SYNTHESIS | Eli Lilly and Company (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-3505533-B1 | SYNTHESIS METHOD FOR LOW-RACEMIZATION IMPURITY LIRAGLUTIDE | SHENZHEN JYMED TECH CO LTD (CN) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024077149-A2 | PEPTIDES FOR INCRETIN SYNTHESIS | ELI LILLY AND COMPANY (US) | 2024-04-11 | — | — | WO | disclosed |
| US-11518794-B2 | Synthesis method for liraglutide with low racemate impurity | Shenzhen JYMed Technology Co., Ltd. (CN) | 2022-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125423-A1 | PEPTIDES FOR INCRETIN SYNTHESIS | IAPP, GLP1R, VIP | CASP3 402/4885PTPN1 1104/4885MDM4 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.